How Bimzelx Stacks Up Against Other Psoriasis Biologics
Bimzelx (bimekizumab) targets both IL-17A and IL-17F cytokines, differing from most psoriasis biologics that block single pathways like IL-17A alone (ixekizumab, secukinumab), IL-23 (guselkumab, risankizumab, tildrakizumab), TNF-alpha (adalimumab, etanercept), or IL-12/23 (ustekinumab).[1][2]
Efficacy in Head-to-Head Trials
Bimzelx shows higher skin clearance rates than some IL-17 and IL-23 inhibitors. In BE VIVID and BE READY trials, 85-91% of patients achieved PASI 90 (90% skin clearance) at week 16, versus 59-70% for secukinumab and 70-80% for adalimumab.[3] Against ustekinumab, BE SURE trial data gave Bimzelx a PASI 90 rate of 85% versus 57%.[4] It also clears scalp and genital psoriasis faster than adalimumab or ustekinumab.[1]
Speed of Response
Bimzelx acts quickest among IL-17 blockers, with 30-40% PASI 75 response by week 4—faster than ixekizumab (20-30%) or secukinumab (25%).[2][5] IL-23 drugs like guselkumab take 8-12 weeks for similar early gains.
Dosing and Convenience
Administered every 4 weeks subcutaneously after initial doses (weeks 0, 4, 8), Bimzelx matches ixekizumab and secukinumab but beats guselkumab (every 8 weeks) and ustekinumab (every 12 weeks).[1] Less frequent dosing reduces injection burden compared to weekly etanercept.
Safety Profile
Common side effects include upper respiratory infections (15-20%) and oral candidiasis (7-14%), higher than IL-23 inhibitors (under 5% for infections).[3][6] Serious infections and IBD risks align with other IL-17 drugs but exceed TNF inhibitors. No increased MACE or malignancy signals in trials up to 2 years.[1]
Who Responds Best and Switching Considerations
Bimzelx excels in moderate-to-severe plaque psoriasis, including tough cases like scalp involvement, where it outperforms secukinumab.[7] Patients switching from IL-17/IL-23 failures see 70-80% PASI 90 recapture.[2] TNF biologics suit those with comorbidities like IBD, where IL-17 drugs risk flares.
Cost and Access
Annual U.S. list price is around $95,000, comparable to Skyrizi (risankizumab, $97,000) and higher than older TNFs like Humira ($80,000).[8] Insurance coverage favors it for non-responders to prior biologics.
| Drug | Target | PASI 90 at Week 16 | Dosing Frequency | Key Edge |
|------|--------|---------------------|------------------|----------|
| Bimzelx | IL-17A/F | 85-91% | Q4W | Fastest clearance, dual block |
| Cosentyx (secukinumab) | IL-17A | 60-70% | Q4W | Good for enthesitis |
| Taltz (ixekizumab) | IL-17A | 70-80% | Q4W | Strong scalp data |
| Tremfya (guselkumab) | IL-23 | 70-80% | Q8W | Lowest infection rates |
| Stelara (ustekinumab) | IL-12/23 | 50-60% | Q12W | Versatile for psoriatic arthritis |
[1]: FDA Bimzelx Label
[2]: NEJM BE SURE Trial
[3]: Lancet BE VIVID/BE READY
[4]: JAMA Dermatology Analysis
[5]: PASI Response Meta-Analysis
[6]: Safety Review
[7]: Scalp Psoriasis Data
[8]: Drugs.com Price Guide